Payment overview · 2025
General Payments
$119.39
6 reported records · 5 companies
Healthcare provider profile · identity verified
Terry Dean Roode, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW BREMEN, OH · NPI 1093749913
Verified facts
What the public records show
CMS Open Payments records show Terry Dean Roode, D.O. received $119.39 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.32 | 32.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.84 | 20.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.12 | 20.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.64 | 14.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.47 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.39 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 408 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 90 |
| Metformin Hcl | Metformin Hcl | 287 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 89 |
| Lisinopril | Lisinopril | 235 | 73 |
| Gabapentin | Gabapentin | 197 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 61 |
| Alprazolam | Alprazolam | 178 | 28 |
| Omeprazole | Omeprazole | 168 | 52 |
| Simvastatin | Simvastatin | 165 | 49 |
| Tramadol Hcl | Tramadol Hcl | 163 | 34 |
| Glimepiride | Glimepiride | 155 | 43 |
| Furosemide | Furosemide | 148 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 31 |
| Sertraline Hcl | Sertraline Hcl | 131 | 42 |
| Meloxicam | Meloxicam | 129 | 44 |
| Warfarin Sodium | Warfarin Sodium | 126 | 25 |
| Allopurinol | Allopurinol | 124 | 40 |
| Potassium Chloride | Potassium Chloride | 120 | 40 |
| Buspirone Hcl | Buspirone Hcl | 109 | 26 |
| Ozempic | Semaglutide | 109 | 20 |
| Losartan Potassium | Losartan Potassium | 108 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 39 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 101 | 30 |
| Eliquis | Apixaban | 89 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 28 |
| Carvedilol | Carvedilol | 80 | 24 |
| Prednisone | Prednisone | 77 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 27 |
| Metformin Hcl Er | Metformin Hcl | 70 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 18 |
| Donepezil Hcl | Donepezil Hcl | 66 | 16 |
| Montelukast Sodium | Montelukast Sodium | 66 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 20 |
| Lorazepam | Lorazepam | 57 | 20 |
| Methylprednisolone | Methylprednisolone | 57 | 44 |
| Atenolol | Atenolol | 53 | 14 |
| Baclofen | Baclofen | 53 | 11 |
| Bumetanide | Bumetanide | 52 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 50 | 14 |
| Mounjaro | Tirzepatide | 50 | 11 |
| Trazodone Hcl | Trazodone Hcl | 49 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 13 |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Famotidine | Famotidine | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Spironolactone | Spironolactone | 42 | 11 |
| Enalapril Maleate | Enalapril Maleate | 41 | 11 |
| Finasteride | Finasteride | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Ramipril | Ramipril | 40 | 13 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 23 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Azithromycin | Azithromycin | 31 | 26 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Glipizide | Glipizide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.39 · 6 records | GlaxoSmithKline, LLC. | AREXVY, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error